Yazar "Karlidag, R." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Evaluation of sexual function in patients presenting with Behcet's disease with or without depression
    (Wiley, 2013) Gul, I. G.; Kartalci, S.; Cumurcu, B. E.; Karincaoglu, Y.; Yologlu, S.; Karlidag, R.
    Aim Sexual dysfunction has been found in many disorders that are chronic or disabling. The aim of this study was to evaluate the sexual satisfaction levels, sexual function and their relationship with the mental state in a group of patients being followed-up with a diagnosis of Behcet's disease (BD). Method A total of 50 BD patients and 50 control-group subjects were administered the Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), Golombok Rust Sexual Satisfaction Scale (GRISS) and Arizona Sexual Experiences Scale (ASEX). Results The ASEX, GRISS total, HDRS and HARS scores were significantly higher in the patient group than the control subjects (P=0.0001, P=0.007, P=0.0001, P=0.0001 respectively). Sexual dissatisfaction was seen in 40 (80%) of the patient-group and 16 (32%) of the control-group subjects according to the GRISS (P=0.0001). Female study participants had higher mean scores than the control subjects for the ASEX, GRISS total scores and the GRISS satisfaction, avoidance, vaginismus and orgasm subscale scores (P=0.0001, P=0.002, P=0.02, P=0.001, P=0.006, P=0.03 respectively). Male study participants had different mean scores for the controls regarding the ASEX scores and the GRISS impotence, premature ejaculation, satisfaction and frequency subscale scores (P=0.01, P=0.01, P=0.0001, P=0.03, P=0.007 respectively). Discussion The negative effect of the disorder on the biological and functional status and daily living activities in BD patients also influences the patients' sexual experiences and satisfaction. The negative effects of chronic diseases such as BD should therefore be defined and the disorder evaluated from a wide perspective during the treatment process.
  • Küçük Resim Yok
    Öğe
    Ketofol (mixture of ketamine and propofol) administration in electroconvulsive therapy
    (Australian Soc Anaesthetists, 2012) Kayhan, G. Erdogan; Yucel, A.; Colak, Y. Z.; Ozgul, U.; Yologlu, S.; Karlidag, R.; Ersoy, M. O.
    The aim of this study was to evaluate the effect of a ketamine:propofol combination ('ketofol') for electroconvulsive therapy on seizure activity, haemodynamic response and recovery parameters, and to compare with these with the effects of propofol alone. Twenty-four patients underwent a total of 144 electroconvulsive therapy sessions, allocated in this prospective, double-blind, crossover study. Patients were randomly assigned to receive 1 mg/kg ketofol (0.5 mg/kg propofol plus 0.5 mg/kg ketamine) or 1 mg/kg propofol 1% for anaesthesia induction. Seizure duration and quality, haemodynamic data, recovery parameters and side-effects were recorded and analysed between groups. Both motor and electroencephalography seizure durations in the ketofol group (29 +/- 17 and 41 +/- 17 seconds, respectively) were similar to that in the propofol group (28 +/- 13 and 38 +/- 16 seconds, respectively). Postictal suppression index was higher in the ketofol group (89.63 +/- 7.88) than in the propofol group (79.74 +/- 14.6) (P <0.05). In the ketofol group, heart rate after the seizure ended and mean arterial pressures, recorded at 0 and 5 minutes after the seizure ended, were higher than in the propofol group. Time to obeying commands was longer in the ketofol group (P <0.05). There were no untoward psychological reactions following ketofol. Although no superiority to propofol in terms of seizure duration, haemodynamic or recovery parameters was found, the ketofol mixture selected in our study provided better seizure quality than propofol. We conclude that ketofol can be an alternative strategy to enhance the seizure quality and clinical efficiency of electroconvulsive therapy.